Neuro, Gfp, Davidal-Do you feel strongly that the conference call (eluded to by Stoll) in mid to late August is only in reference to the IND filing? Is that a normal procedure?
It seems that if they were going to round up investors, analysts etc., it would be regarding something more important-such as the FDA's acceptance of the IND, a partnership, or progress on CX-701.